Overview

Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy

Status:
NOT_YET_RECRUITING
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy
Phase:
PHASE2
Details
Lead Sponsor:
Fudan University
Treatments:
Dexamethasone
netupitant, palosentron drug combination
Olanzapine
Tablets